Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single–Center retrospective cohort study

BACKGROUND: Rivaroxaban is a novel oral anticoagulant (NOAC) that is commonly used for stroke prevention among patients with atrial fibrillation (AF). However, its cost effectiveness in reducing the risk of hospitalization and mortality in comparison to warfarin among nonvalvular AF patients in Saud...

Descripción completa

Detalles Bibliográficos
Autores principales: AlRuthia, Yazed, AlOtaibi, Bushra Q., AlOtaibi, Reem M., AlOtaibi, Najla Q., Alanazi, Miteb, Asaad Assiri, Ghadah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845109/
https://www.ncbi.nlm.nih.gov/pubmed/36685295
http://dx.doi.org/10.1016/j.jsps.2022.11.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845109/
https://www.ncbi.nlm.nih.gov/pubmed/36685295
http://dx.doi.org/10.1016/j.jsps.2022.11.010

Ejemplares similares